Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy? ; day:3 ; month:1 ; year:2019 ; pages:1-11
European journal of nuclear medicine and molecular imaging ; (3.1.2019), 1-11
- Urheber
-
Santos, José Carlos dos
Schäfer, Martin
Bauder-Wüst, Ulrike
Lehnert, Wencke
Leotta, Karin
Morgenstern, Alfred
Kopka, Klaus
Haberkorn, Uwe
Mier, Walter
Kratochwil, Clemens
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-018-4220-z
- URN
-
urn:nbn:de:101:1-2019020819270481338124
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Santos, José Carlos dos
- Schäfer, Martin
- Bauder-Wüst, Ulrike
- Lehnert, Wencke
- Leotta, Karin
- Morgenstern, Alfred
- Kopka, Klaus
- Haberkorn, Uwe
- Mier, Walter
- Kratochwil, Clemens
- SpringerLink (Online service)
Ähnliche Objekte (12)
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Image-based dosimetry for 225Ac-PSMA-I&T therapy using quantitative SPECT
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3
Structural modifications of PSMA ligands to optimize their pharmacokinetics
PSMA ligands for diagnosis and therapy of prostate cancer
2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617